Dr. Maier joined Alnylam Pharmaceuticals in 2006 where he currently serves as Senior Vice President, heading the Oncology group. Dr. Maier has contributed to the development of lipid nanoparticles and GalNAc conjugates, two clinically validated platforms for siRNA delivery, as well as the advancement of multiple therapeutic programs to development, which has resulted in the approval of five RNAi therapeutics to date.

After receiving his Ph.D. in Organic Chemistry in 1997 at the University of Tübingen, Germany, Martin moved to the U.S. for his postdoctoral research at Isis (now Ionis) Pharmaceuticals, where he subsequently assumed a permanent position working on novel chemistries and delivery systems for antisense oligonucleotides.

During Martin’s 25 years of experience in the field of oligonucleotide therapeutics, he has contributed to the advancement of therapeutic nucleic acids across both, ASO and RNAi platforms. He is the author of more than 90 peer-reviewed scientific publications, reviews and book chapters and inventor on more than 40 issued patents.